parp inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without...
Published 5 years ago • 172 plays • Length 5:32Download video MP4
Download video MP3
Similar videos
-
4:23
comment: parp inhibitor olaparib plus bevacizumab in women with ovarian cancer
-
8:41
parp inhibitors for ovarian cancer: use of olaparib
-
3:42
parp maintenance bevacizumab in ovarian cancer
-
2:27
the paola-1 study: olaparib and bevacizumab for ovarian cancer
-
5:40
parp inhibitor combo shows early promise for patients with and without brca mutations
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
6:01
olaparib and bevacizumab: on the horizon for treating ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
3:37
selecting patients to be treated with maintenance olaparib in the paola-1 trial
-
1:08
using parp inhibitors to improve quality of life for patients with metastatic breast cancer
-
4:19
treating brca breast cancer with parp inhibition
-
4:26
more ovarian cancer patients benefit from maintenance combined targeted therapy
-
10:34
solo1: maintenance olaparib in advanced brca ovarian cancer
-
0:46
parp inhibitor rechallenging in ovarian cancer
-
5:55
maintenance therapy: parp inhibitor or bevacizumab
-
6:04
when to add bevacizumab for recurrent ovarian cancer
-
1:22
overcoming resistance to parp inhibition in ovarian cancer
-
8:33
the standard of care and progress so far with parp inhibitors for ovarian cancer
-
6:43
olaparib and investigational pi3k inhibitor bkm120 combination active against ovarian